ArticleCell death & disease2022

Single-cell profiling of immune cells after neoadjuvant pembrolizumab and chemotherapy in IIIA non-small cell lung cancer (NSCLC).

Zhenzhen Hui et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.